Showing 971-980 of 2351 results for "".
- AD Pipeline Watch: Apogee Therapeutics, Inc.’s IL-13 Blocker Enters Phase 1 Trialhttps://practicaldermatology.com/news/ad-pipeline-watch-apogee-therapeutics-incs-il-13-blocker-enters-phase-1-trial/2461911/The first volunteers have been dosed in a Phase 1 trial for
- Advanced Aesthetic Technologies, Inc.’s Algeness Named Top Finalist in Terra2 Solution Skin Health Innovation Competitionhttps://practicaldermatology.com/news/advanced-aesthetic-technologies-incs-algeness-named-top-finalist-in-terra2-solution-skin-health-innovation-competition/2460708/Advanced Aesthetic Technologies, Inc. (AAT) and Algeness are finalists in the recent Terra2 Solutions Skin Health Innovation Competition. Algeness is a patented family of fully resorbable injectable gel implant dermal fillers that are 100% natural and based on purified agarose with
- Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and ADhttps://practicaldermatology.com/news/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4s-role-in-hs-and-ad/2460411/Kymera Therapeutics Inc. has started enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally administered IRAK4 degraders for the treatment of toll-like
- Ortek Therapeutics Files Patent Applications for New Microbiome to Reduce S. Aureus Proliferationhttps://practicaldermatology.com/news/ortek-therapeutics-files-patent-applications-for-new-microbiome-to-reduce-s-aureus-proliferation/2458808/Stony Brook University and Ortek Therapeutics, Inc. filed two patent applications in the United States and internationally for nutrient based compositions utilizing innovative microbiome technology. Developed at Stony Brook University, these compositions have been exclusively licensed to Ortek as
- Data Demonstrate Efficacy of ON Light Sciences, Inc.'s DeScribe Transparent PFD Patchhttps://practicaldermatology.com/news/data-demonstrate-efficacy-of-on-light-sciences-incs-describe-transparent-pfd-patch/2458839/Results of a clinical study evaluating the potential role of a Perfluorodecalin (PFD)-infused gel patch in laser-assisted tattoo removal were presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting. “It is estimated that close to 25% of the US population has
- Amgen Launches The Enbrel Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjectorhttps://practicaldermatology.com/news/amgen-launches-the-enbrel-mini-single-dose-prefilled-cartridge-with-autotouch-reusable-autoinjector/2457966/Amgen's Enbrel Mini with AutoTouch is now available in the United States. Awarded the Arthritis Foundation Ease of Use Commendation, this new and innovative delivery system provides an additional administration option for appropriate Enbrel patients. T
- Topix Pharmaceuticals Rolls Out Replenix RetinolForte Treatment Serumhttps://practicaldermatology.com/news/topix-pharmaceuticals-rolls-out-replenix-retinolforte-treatment-serum/2458242/Topix Pharmaceuticals is adding Replenix® RetinolForte Treatment Serum to their portfolio of offerings. The serum’s patent-pending, time-released Micropolymer delivery system deposits retinol into t
- UofL Dermatology Chief Tapped by ACCMEhttps://practicaldermatology.com/news/uofl-dermatology-chief-tapped-by-accme/2458477/Jeffrey P. Callen, MD, chief of the Division of Dermatology at the University of Louisville School of Medicine in Kentucky, has been elected to serve on the Accreditation Review Committee (ARC) of the Accreditation Council of Continuing Medical Education (ACCME).
- Modernizing Medicine Reveals Telemedicine Component for its EMRhttps://practicaldermatology.com/news/modernizing-medicine-reveals-telemedicine-component-for-its-emr/2458890/Modernizing Medicine, Inc. revealed a new t
- EADV News: Bimekizumab Achieves High Thresholds of Clinical Response in HShttps://practicaldermatology.com/news/eadv-news-bimekizumab-achieves-high-thresholds-of-clinical-response-in-hs/2462067/UCB’s Bimekizumab treatment results in clinically meaningful improvements in Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) and the more stringent HiSCR75, HiSCR90 and HiSCR100 compared with placebo at Week 16, with improvements increasing for patients remaining in the study t